| STUDY NUMBER | DOCUMENT TYPE | STUDY TITLE | STUDY SPONSOR |
| 100002 | Protocol | Adjuvant CAF for Pathologic Stage II, Node+ Breast Cancer: Randomization Among Intensive CAF for Four Cycles vs. Low-Dose CAF for Four Cycles vs. Standard-Dose CAF for Four Cycles | |
| 100007 | Protocol | A Study of the Natural History and a Phase II Trial of Melphalan and Secondary Treatment with Cisplatin in Patients with Progressive Disease | |
| 100008 | Protocol | Treatment of Adv Hodgkin's Disease: A Randomized Trial Comparing MOPP vs. ABVD vs. MOPP Alternating with ABVD | |
| 100011 | Protocol | Randomized Clinical Trial for the Treatment of Women with Selected Stage IC and II(A, B, C) and Selected Stage IA and IIB Ovarian Cancer, Phase III | |
| 100023 | Protocol | IP Cis-platinum/IV Cyclophosphamide Vs. IV IP Cis-platinum/IV in Non-Measurable (Optimal) Disease Stage III Ovarian Cancer | |
| 100031 | Protocol | Cytogenetic Studies in Acute Leukemia | |
| 100032 | Protocol | Adj Chemotx +/- Endocrine High Risk, Node Negative Breast Cancer with Observation | |
| 100035 | Protocol | Phase III Protocol for the Evaluation of Combined Modalities in the Treatment of Surgically Resected Colonic Carcinoma with Positive Nodes, Dukes' C | |
| 100038 | Protocol | A Randomized, Comparative Study of High Dose CPA/CDDP/BCNU and ABMs Versus Standard Dose CPA/CDDP/BCNU as Consolidation to Adjuvant CAF for Patients with Operable Stage II or Stage III Breast Cancer Involving >= 10 Axillary Lymph Nodes | |
| 100052 | Protocol | Acquisition of Human Gynecologic Specimens and Serum to Be Used in Studying the Causes, Diagnosis, Prevention and Treatment of Cancer | |
| 100059 | Protocol | A Phase III Trial of Intensification Therapy with Cytosine Arabinoside Alone Vs. a Sequential Combination of Cytosine Arabinoside with Cyclophosphamide/Etoposide; Mitoxantrone/Diaziquone in Patients < 60 Years of Age with Acute Myeloid Leukemia in First R | |
| 100067 | Protocol | DA7 Immunotoxin PED/Adult Refractory T-Cell
Treatment of Therapy-Refractory T Lineage Acute Lymphostatic Leukemia (ALL) or Lymphoma with DA7 Immunotoxin | |
| 100074 | Protocol | A Phase III Randomized Study of Whole Abdominal Radiotherapy (WAR) Versus Combination Ifosfamide-Mesna with Cisplatin in Optimally Debulked Stage I, II, III, or IV Carcinosarcoma (CS) of the Uterus | |
| 100075 | Protocol | Randomized Trial of Subtotal Nodal Irradiation Vs. Doxorubicin Plus Vinblastine and Subtotal Nodal Irradiation for Stage I-IIA Hodgkin's Disease - Phase III | |
| 100076 | Protocol | Phase II Study of Cyclophosphamide, Prednisone, and Infusional Doxorubicin, Vincristine, and Etoposide (i-CHOPE) In Diffuse Lymphomas Relapsed/Refractory to Bolus Therapy | |
| 100077 | Protocol | Women's Intervention Nutrition Study (WINS): A Clinical Trial to Determine the Efficacy of a Dietary Fat Reduction Program Provided in Addition to Systemic Adjuvant Therapy in the Management of Patients with Primary Invasive Breast Cancer | |
| 100082 | Protocol | Phase III Intergroup Prospectively Randomized Trial of Perioperative 5-FU After Curative Resection, Followed by 5-FU/Leucovorin for Patients with Colon Cancer | |
| 100083 | Protocol | Phase III Comparison of Adjuvant Chemotherapy with High-dose Cyclophosphamide Plus Doxorubicin (AC) Versus Sequential Doxorubicin Followed by Cyclophosphamide (A->C) in High-Risk Breast Cancer Patients with 0 - 3 Positive Nodes (Intergroup) | INT |
| 100084 | Protocol | Standard Dose Vs. Myeloablative Therapy for Previously Untreated Symptomatic Multiple Myeloma | |
| 100085 | Protocol | A Phase III Randomized Study of Cisplatin (NSC #119875) and Taxol (Paclitaxel) (NSC #125973) with Interval Secondary Cytoreduction Versus Cisplatin and Paclitaxel in Patients with Suboptimal Stage III Epithelial Ovarian Carcinoma | |
| 100087 | Protocol | Doxorubicin Dose Escalation, With or Without Taxol, as Part of the CA-Adjuvant Chemotherapy Regimen for Node-Positive Breast Cancer: A Phase III Intergroup Study | |
| 100091 | Protocol | Phase III Comparison of CAF and a 16-Week Multi-Drug Regimen as Adjuvant Therapy for Patients with Hormone Receptor Negative, Node-Positive Breast Cancer | |
| 100092 | Protocol | CAF Vs CAF + Zoladex?Premenop... Auxillary Node + Recepter+Breadt ca | |
| 100093 | Protocol | Phase III Comparison of Adjuvant Chemoendocrine Therapy with CAF and Concurrent or Delayed Tamoxifen to Tamoxifen Alone in Postmenopausal Patients with Involved Axillary Lymph Nodes and Positive Receptors: An Intergroup (SWOG, ECOG, CALGB, NCCTG, NCIC) St | |
| 100097 | Protocol | Whole-Abdominal Radiotherapy (WAR) Vs. Combination Doxorubicin-Cisplatin Chemotherapy in Advanced Endometrial Carcinoma (Phase III) | |
| 100098 | Protocol | A Randomized Comparison of Radiation Therapy and Adjuvant Hysterectomy Versus Radiation Therapy and Weekly Cisplatin and Adjuvant Hysterectomy in Patients with Bulky Stage IB Carcinoma of the Cervix | |
| 100103 | Protocol | Postoperative Evaluation of 5-FU by Bolus Injection Vs. 5-FU by Prolonged Venous Infusion Prior to and Following Combined Prolonged Venous Infusion Plus Pelvic XRT Vs. Bolus 5-FU Plus Leucovorin Plus Levamisole Prior to and Following Combined Pelvic XRT i | |
| 100107 | Protocol | All-Trans Retinnin Acid Versus ARA-C + DNR Induction for Untreated APL | |
| 100111 | Protocol | A Phase III Comparison Between Concurrent Chemotherapy Plus Radiotherapy, and Concurrent Chemotherapy Plus Radiotherapy Followed by Surgical Resection for Stage IIIA (N2) Non-Small Cell Lung Cancer | |
| 100116 | Protocol | A Phase III Randomized Study of Cisplatin and Paclitaxel (24-Hour Infusion) Versus Carboplatin and Paclitaxel (3-Hour Infusion) in Optimal Stage III Epithelial Ovarian Carcinoma | |
| 100117 | Protocol | A Randomized Phase III Trial of Carboplatin (AUC 7.5) and Pacitaxel 175mg/m2 q21 Days x 3 Courses Versus the Same Regimen x 6 Courses, in Patients with Selected Stage IC and II (A,B,C) and Selected IA and IB Ovarian Cancer | |
| 100133 | Protocol | A Pilot Trial with Limited Pharmacokinetic Monitoring of PEG-Asparaginase During Remission Induction and Consolidation Chemotherapy for Adult Acute Lymphoblastic Leukemia | |
| 100134 | Protocol | Breast Adjuvant Node Positive Adriamycin/Cytoxan +/- Paclitaxel | |
| 100147 | Protocol | A Randomized Trial Comparing Preoperative Doxorubicin (Adriamycin) Cyclophosphamide (AC) to Preoperative AC Followed by Preoperative Docetaxel (Taxotere) and to Preoperative AC Followed by Postoperative Docetaxel in Patients with Operable Carcinoma of the | |
| 100161 | Protocol | The CALGB Leukemia Tissue Bank | |
| 100177 | Protocol | Phase III Study of Adjuvant Chemotherapy After Resection for Patients with T2N0 Stage I Non-Small Cell Carcinoma of the Lung | |
| 100181 | Protocol | Treatment of Patients with Suboptimal (Bulky) Stage IB Carcinoma of the Cervix: A Randomized Comparison of Radical Hysterectomy and Pelvic and Para-Aortic Lymphadenectomy With or Without Neoadjuvant Vincristine and Cisplatin Chemotherapy (Phase III) | |
| 100192 | Protocol | Phase I Study of MDR Modulation with PSC-833 (NSC #648265) with a Pilot Study of Cytogenetic Risk-Adapted Consolidation Followed by a Phase II Pilot Study of Immunotherapy with rIL-2 (NSC #373364) in Previously Untreated Patients with AML < 60 Years | |
| 100204 | Protocol | Phase III Trial to Reserve the Larynx: Induction Chemotherapy and Radiation Therapy Versus Concomitant Chemotherapy and Radiation Therapy Versus Rad Therapy | |
| 100212 | Protocol | A Randomized Comparison of Radiation Vs. Radiation Plus Weekly Cisplatin Vs. Standard Radiation Plus PVI (Protracted Venous Infusion) 5-FU in Patients with Stage II-B, III-B and IV-A Carcinoma of the Cervix | |
| 100215 | Protocol | A Phase III Trial of CHOP Versus CHOP and Chimeric Anti-CD20 Monoclonal Antibody (IDEC-C2B8) in Older Patients with Diffuse Mixed, Diffuse Large Cell and Immunoblastic Large Cell Histology Non-Hodgkin's Lymphoma | |
| 100217 | Protocol | A Randomized Phase III Trial of Sequential Chemotherapy Using Doxorubicin, Paclitaxel, and Cyclophosphamide or Concurrent Doxorubicin and Cyclophosphamide Followed by Paclitaxel at 14- or 21-Day Intervals in Women with Node-Positive Stage II/IIIA Breast C | |
| 100224 | Protocol | A Randomized Phase II Study of Concurrent Fludarabine + Chimeric Anti-CD20 Monoclonal Antibody IDEC-C2B8 (Rituximab) Induction Followed by Rituximab Consolidation Versus Fludarabine Induction Followed by Rituximab Consolidation in Untreated Patients with | |
| 100238 | Protocol | A Phase III Study of Surgical Resection and Chemotherapy (Paclitaxel And Carboplatin) With or Without Adjuvant Radiotherapy for Resected Stage IIIA Non-Small Cell Lung Cancer | |
| 100247 | Protocol | Phase II Chemoradiation Trial Using Gemcitabine in Patients with Locoregional Adenocarcinoma of the Pancreas | |
| 100249 | Protocol | A Randomized Study of Doxorubicin Plus Cisplatin Versus Doxorubicin Plus 3-Hour Paclitaxel Plus G-CSF Support in Patients with Primary Stage III and IV or Recurrent Endometrial Carcinoma | |
| 100252 | Protocol | A 3-Arm Randomized Trial to Compare Adjuvant Adriamycin and Cyclophosphamide Followed by Taxotere (AC-T); Adriamycin and Taxotere (AT); and Adriamycin, Taxotere, and Cyclophosphamide (ATC) in Breast Cancer Patients with Positive Auxiliary Lymph Nodes | |
| 100254 | Protocol | A Phase III Randomized Double Blind Study of Letrozole Versus Placebo in Women with Primary Breast Cancer Completing Five or More Years of Adjuvant Tamoxifen (NCIC CTG MA.17) | |
| 100258 | Protocol | Phase III Study of Adriamycin/ Taxotere Vs. Adriamycin/Cytoxan for the Adjuvant Treatment of Node Positive or High Risk Node Negative Breast Cancer | |
| 100260 | Protocol | Study of Tamoxifen & Raloxifene (STAR) for the Prevention of Breast Cancer | |
| 100262 | Protocol | Minimally Invasive Molecular Staging (MIMS) RT-PCR Breast Cancer Study | |
| 100264 | Protocol | Prognostic Significance of Endorectal MRI in Predicting Outcome After Combined Radiation and Androgen Suppression for Prostate Cancer: A Prospective Phase II Study | |
| 100274 | Protocol | Expression of the MN Protein in Atypical Glandular Cells of Undetermined Significance (AGUS or AGCUS) as a Potential Diagnostic Biomarker of Cervical Dysplasia/Neoplasia | |
| 100290 | Protocol | A Phase III Study of Doxorubicin-Cyclophosphamide Therapy Followed by Paclitaxel or Docetaxel Given Weekly or Every 3 Weeks in Patients with Axillary Node-Positive or High Risk Node Negative Breast Cancer | |
| 100292 | Protocol | A Prospective Study of the Prognostic Significance of Occult Metastases in the Patient with Resectable Non-Small Cell Lung Carcinoma | |
| 100297 | Protocol | Clinical Efficay of Molecular Analysis of Surgical Margins and Regional Lymph Nodes in Management of Head and Neck Squamous Cell Carcinoma | |
| 100299 | Protocol | A Randomized Phase III Study of Tumor Volume Directed Pelvic Plus or Minus Para-Aortic Irradiation Followed by Cisplatin, Doxorubicin, or Cisplatin, Doxorubicin and Paclitaxel for Advanced Endometrial Carcinoma | |
| 100300 | Protocol | Phase III Trial of Doxorubicin and Cyclophosphamide (AC) Followed by Weekly Paclitaxel With or Without Trastuzumab as Adjuvant Treatment for Women with HER-2 Overexpressing or Amplified Node Positive or High-Risk Node Negative Breast Cancer | |
| 100309 | Protocol | Intraoperative Lymphatic Mapping and Sentinel Node (SN) Identification in Patients with Squamous Cell Carcinoma of the Vulva | |
| 100314 | Protocol | Molecular Markers of Pleural Involvement in Resected Non-Small Cell Lung Cancer | |
| 100332 | Protocol | A Phase III Randomized Trial of Paclitaxel and Carboplatin Vs. Triplet or Sequential Doublet Combinations in Patients with Epithelial Ovarian or Primary Peritoneal Carcinoma | |
| 100614 | Protocol | Phase II Study of PEG-Interferon, GM-CSF and Thalidomide in Metastatic Renal Cell Carcinoma | |
| 100615 | Protocol | Phase II Study of Gemcitabine and CPT-11 (Irinotecan) in Locally Advanced and Metastatic Bladder Cancer | |
| 100617 | Protocol | A Randomized Phase III Trial of Surgery Alone or Surgery Plus Preoperative Paclitaxel/Carboplatin in Clinical Stage IB (T2N0), II (T1-2N1, T3N0) and Selected IIIA (T3N1) Non-Small Cell Lung Cancer (NSCLC) | |
| 100619 | Protocol | A Phase III Study of Delayed Vs. Immediate Second-Line Therapy with Docetaxel After Gemcitabine + Carboplatin in Advanced Non-Small Cell Lung Cancer | |
| 100642 | Protocol | A Phase III Trial to Evaluate the Efficacy of Maintaining Hemoglobin Levels Above 120 G/L With Erythropoietin Versus Above 100 G/L Without Erythropoietin in Anemic Patients Receiving Concurrent Radiation and Cisplatin for Cervical Cancer | |
| 100671 | Protocol | Lung Cancer Specimen Repository Protocol, Ancillary | |
| 100672 | Protocol | A Phase III of Cisplatin/Etoposide/Radiotherapy with Consolidation Docetaxel Followed by Maintenance Therapy with ZD1839 (NSC-715055) or Placebo in Patients with Inoperable Locally Advanced Stage III Non-Small Cell Lung Cancer (NSCLC) | |
| 100687 | Protocol | A Prognostic Study of Sentinel Node and Bone Marrow Micrometastases in Women with Clinical T1 or T2 N0 M0 Breast Cancer | |
| 100688 | Protocol | Phase II Evaluation of Early Oral Estramustine, Oral Etoposide and Intravenous Paclitaxel in Combination With Hormone Therapy in Patients with High-Risk Metastatic Adenocarcinoma of the Prostate. | |
| 100700 | Protocol | Phase III Randomized Trial of Concomitant Radiation, Cisplatin, and Tirapazamine (SR259075) versus Concomitant Radiation and Cisplatin in Patients with Advanced Head and Neck Cancer | |
| 100701 | Protocol | A Randomized Phase III Trial of Gemzar Versus Doxil with Crossover Treatment Option for Patients with Platinum-Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer Undergoing Second or Third-Line Chemotherapy | |
| 100704 | Protocol | Contemporary Screening for the Detection of Lung Cancer | |
| 100705 | Protocol | An Open-Label, Randomized, Multicenter Study to Evaluate the Use of Zoledronic Acid in the Prevention of Cancer Treatment-Related Bone Loss in Postmenopausal Women with ER+ and/or PR+ Breast Cancer receiving Letrozole as Adjuvant Therapy | |
| 100708 | Protocol | A Randomized Phase III Trial of ABVD Versus Stanford V +/- Radiation Therapy in Locally Extensive and Advanced Stage Hodgkin's Disease | |
| 100718 | Protocol | A trial of Lymphatic Mapping and Sentinel Node Lymphadenectomy for Patients with T1 or T2 Clinically N0 Oral Cavity Squamous Cell Carcinoma | |
| 100723 | Protocol | A Double-Blind, Randomized, Vehicle-Controlled Study Comparing the Safety and Efficacy of Benzydamine Hydrochloride 0.15% Oral Rinse Including a Separate Open-Label Standard of Care Arm in Subjects with Radiation-Induced Oral Mucositis | |
| 100729 | Protocol | A Phase III Comparison of Prophylactic Cranial Irradiation Versus Observation in Patients with Locally Advanced Non-small Cell Lung Cancer | |
| 100730 | Protocol | Phase II Study of Gemcitabine and Cpt-11 (Irinotecan) in Unresectable or Metastatic Renal Cell Carcinoma. | |
| 100737 | Protocol | Randomized Phase III Study of Cisplatin and Irinotecan (NSC-616348) Versus Cisplatin and Etoposide in Patients with Extensive Stage Small Cell Lung Cancer (E-SCLC | |
| 100740 | Protocol | A Phase III Prospective Randomized, Double -Blind, Placebo-Controlled Trial of the Epidermal Growth Factor Receptor Antagonist, ZD1839 (IRESSA) in Completely Resected Primary Stage IB, II and IIIA Non-Small Cell Lung Cancer | |
| 100746 | Protocol | A Phase III Randomized Double-blind Study of Adjuvant STI571 (Gleevec) Versus Placebo in Patients Following The Resection of Primary GastroIntestinal Stromal Tumor (GIST) | |
| 100748 | Protocol | Cyclophosphamide and Doxorubicin (CA) (4 Vs 6 Cycles) Versus Paclitaxel (4 Vs. 6 Cycles) as Adjuvant Therapy For Women with Node-Negative Breast Cancer: A 2X2 Factorial Phase III Randomized Study | |
| 100757 | Protocol | Stabilization of Bcl-2 mRNA in Human Leukemia and Lymphoma | |
| 100760 | Protocol | Evaluation of Biomarkers in Head and Neck Squamous Cell Carcinoma Using Laser Capture Microdissection | |
| 100763 | Protocol | A Randomized Phase III Trial of Paclitaxel Plus Cisplatin Versus Vinorelbine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Versus Topotecan Plus Cisplatin in Stage IVB, Recurrent or Persistent Carcinoma of the Cervix | |
| 100765 | Protocol | A Molecular Staging Study of Endometrial Carcinoma | |
| 100772 | Protocol | Open-Label, Single-Arm Study of the Safety and Efficacy of CC-5013 Monotherapy for Subjects with Multiple Myeloma: A Companion Study for Studies THAL-MM-003, CC-5013-MM-009, and CC-5013-MM-010 | |
| 100776 | Protocol | Phase III Randomized Study of Adjuvant Biologic Therapy in Patients with Stages III/IV Head and Neck Squamous Cell Carcinoma | |
| 100779 | Protocol | A Multicenter, Randomized, Phase II Study to Evaluate the Efficacy and Safety of Taxotere/Carboplatin Combination Therapy and Sequential Therapy with Taxotere then Carboplatin as Second-Line Treatment of Patients with Relapsed, Platinum-Sensitive Ovarian Cancer | |
| 100780 | Protocol | A Phase I Study of Topotecan in Combination with Vinorelbine in Recurrent Lung Cancer | |
| 100783 | Protocol | Phase I Trial of Concurrent Taxotere with Radiation Therapy and Hormonal Therapy for Clinically Localized High risk Prostate Cancer | |
| 100788 | Protocol | A Phase III, Randomized Study of Gemcitabine [fixed-dose rate infusion] and Oxaliplatin (NSC 266046) versus Gemcitabine [fixed-dose rate infusion] versus Gemcitabine [30-minute infusion] in Pancreatic Carcinoma | |
| 100799 | Protocol | A Multi-Center, Multi-National, Double-Blind, Randomized Phase III Study of Satraplatin Plus Prednisone or Placebo Plus Prednisone in Patients with Hormone Refractory Prostate Cancer Previously Treated with One Cytotoxic Chemotherapy Regimen | |
| 100802 | Protocol | A Phase III Randomized Study of TLK286 Versus Gefitinib (Iressa) as Third-Line Therapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer | |
| 100805 | Protocol | A 2 x 2 Factorial Randomized Phase III Study of Inermittent Oral Capecitabine in Combination with Intravenous Oxaliplatin (Q3W) (Xelox) with/without Intravenous Bevacizumab (Q3W) versus Bolus and Continuous Infusion Fluorouracil/Intravenous Leucovorin w | |
| 100808 | Protocol | A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Darbepoetin alfa for the Treatment of Anemia of Cancer | |
| 100815 | Protocol | A Phase II Study of OSI-774 (NSC-718781) in Patients With Locally Advanced or Metastatic Papillary Histology Renal Cell Cancer | |
| 100816 | Protocol | A Randomized, Open-Label Study of Oral CEP-701 Administered in Sequence With Standard Chemotherapy to Patients With Relapsed Acute Myeloid Leukemia (AML) Expressing FLT-3 Activating Mutations | |
| 100818 | Protocol | A Phase III Study of Daunobrubicin and Cytarabine +/- G3139 (Genasense, Oblimersen Sodium, NSC#683428, IND#58842), A BCL2 Antisense Ogigodeoxynucleotide, in Previously Untreated Patients with Acute Myeloid Leukemia (AML) >= 60 Years | |
| 100822 | Protocol | VELCADE (bortezomib) for Injection Therapy for Early Relapsed Prostate Cancer | |
| 100824 | Protocol | A Phase II Study of Tirapazamine (NSC-130181)/Cisplatin/Etoposide and Concurrent Thoracic Radiotherapy for Limited Stage Small Cell Lung Cancer | |
| 100825 | Protocol | Phase I Trial of Bortezomib (VELCADE TM) and Celecoxib in Patients with Advanced Solid Tumors | |
| 100826 | Protocol | A Phase II Study of Oxaliplatin in Combination with Gemcitabine in Unresectable Hepatocellular Carcinoma | |
| 100829 | Protocol | A Phase II Study of XELOX in Locally Advanced or Metastatic Gastric Cancer | |
| 100832 | Protocol | Molecular Detection of NSCLC in Peripheral Blood | |
| 100834 | Protocol | An Open-Label Extended-Use Study of Oral CEP-701 in Patients With Hematologic and Non-Hematologic Malignancies Who Have Completed a Clinical Study of CEP-701 | |
| 100837 | Protocol | A Phase III Study of the Addition of Gemtuzumab Ozogamicin (Mylotarg) Induction Therapy Versus Standard Induction with Daunomycin and Cytosine Arabinoside Followed by Consolidation and Subsequent Randomization to Post-Consolidation Therapy with Gemtuzumab | |
| 100838 | Protocol | A Phase II Study of Gemcitabine in Combination with Doxorubicin for Patients with Head and Neck Cancer | |
| 100840 | Protocol | Use of Proteomic Analysis of Serum Samples for Detection of Non-Small Cell Lung Cancer | |
| 100841 | Protocol | Cytogenic Studies in Leukemia Patients | |
| 100842 | Protocol | Leukemia Centralized Reference Laboratories and Tissue Repositories, Ancillary | |
| 100851 | Protocol | A Phase III Randomized Trial of Induction Chemotherapy with Gemcitabine and Carboplatin Followed by Elective Paclitaxel Consolidation versus Paclitaxel and Carboplatin Followed by Elective Paclitaxel Consolidation in Patients with Primary Epithelial Ovarian, Primary Peritoneal Cancer or Fallopian Tube Carcinoma | |
| 100855 | Protocol | Phase II Trial of Arsenic Trioxide and 5-Azacitidine in Patients with Myelodysplastic Syndrome | |
| 100860 | Protocol | A Randomized Trial Comparing Preservation Of Function
Status After Either Medpulser® Electroporation With
Intratumoral Bleomycin Therapy Or Surgery In Patients With
Locally Recurrent Or Second Primary Squamous Cell
Carcinoma Of The Anterior Oral Cavity, Soft Palate, Or Tonsil That Have Failed Primary Curative Therapy | |
| 100861 | Protocol | A Randomized Trial Comparing Preservation Of Function
Status After Either Medpulser® Electroporation With
Intratumoral Bleomycin Therapy Or Surgery In Patients With
Locally Recurrent Or Second Primary Squamous Cell
Carcinoma Of the Base-Tongue, Posterior Lateral Pharyngeal Wall, Hypopharynx, and Larynx That Have Failed Primary Curative Therapy
| |
| 100864 | Protocol | A Phase III, Adjuvant Trial Comparing Three Chemotherapy Regimens in Women with Node-Positive Breast Cancer: Docetaxel/Doxorubicin/Cyclophosphamide (TAC); Dose-Dense (DD) Doxorubicin/Cyclophosphamide Followed By DD Paclitaxel (DD AC->P); DD AC Followed By | |
| 100865 | Protocol | A Phase II Randomized Trial of Surgery Followed by Chemoradiotherapy Plus C225 (Cetuximab) for Advanced Squamous Cell Carcinoma of the Head and Neck | |
| 100866 | Protocol | Phase II Selection Design Trial of Concurrent Chemotherapy + Cetuximab vs. Chemotherapy Followed by Cetuximab in Advanced Non-Small Cell Lung Cancer (NSCLC) | |
| 100867 | Protocol | A Phase II b Study of Molecular Responses to Imatinib at Standard or Increased Doses for Previously Untreated Patients With Chronic Myelogenous Leukemia (CML) in Chronic Phase | |
| 100868 | Protocol | Intergroup Randomized Phase III Study of Postoperative Irinotecan, 5-Fluorouracil and Leucovorin vs Oxaliplatin, 5-Fluorouracil and Leucovorin vs 5-Fluorouracil and Leucovorin for Patients with Stage II or III Rectal Cancer Receiving Either Preoperative R | |
| 100869 | Protocol | A Randomized Phase III Trial of Oxaliplatin (OXAL) Plus 5-Fluorouracil (5-FU)/Leucovorin (CF) with or without Cetuximab (C225) after Curative Resection for Patients with Stage III Colon Cancer | |
| 100873 | Protocol | A Phase III Trial of CHOP + Rituximab vs CHOP + Iodine-131-Labeled Monoclonal Anti-B1 Antibody (Tositumomab) for Treatment of Newly Diagnosed Follicular Non-Hodgkin's Lymphomas (THE CHOP ONLY ARM OF THIS STUDY WAS PERMANENTLY CLOSED, EFFECTIVE 12/15/02) | |
| 100874 | Protocol | A Randomized, Multicenter, Open-label Study of YONDELIS (ET-743 ecteinascidin) Administered by 2 Different Schedules (Weekly for 3 of 4 weeks vs q 3 Weeks) in Subjects With Locally Advanced or Metastatic Liposarcoma or Leiomyosarcoma Following Treatment W | |
| 100878 | Protocol | Cetuximab as a Second Line Therapy in Patients with Metastatic Esophageal Cancer - Phase II | |
| 100880 | Protocol | A Randomized Phase III Trial of Maintenance Chemotherapy Comparing 12 Monthly Cycles of Single Agent Paclitaxel or Xyotax TM (CT-2103) (IND 70177), Vs No Treatment Until Documented Relapse in Women With Advanced Ovarian or Primary Peritoneal Cancer Who Achieve a Complete Clinical Response to Primary Platinum-Taxane Chemotherapy | |
| 100882 | Protocol | Phase I Trial of Bortezomib (PS-341; NSC 681239) and Flavopiridol (NSC 649890) in Patients with Recurrent or Refractory Indolent B-cell Neoplasms | |
| 100883 | Protocol | Randomized Phase III Trial of Doxorubicin/Cisplatin/Paclitaxel and G-CSF Vs Carboplatin/Paclitaxel in Patients with Stage III & IV or Recurrent Endometrial Cancer | |
| 100885 | Protocol | Phase III Randomized Trial of Concomitant Radiation, Cisplatin and Tirapazamine (SR259075) Vs Concomitant Radiation and Cisplatin in Patients with Advanced Head and Neck Cancer | |
| 100888 | Protocol | An Open-Label Multicenter Randomized Phase 3 Study Comparing the Combination of DOXIL/CAELYX and YONDELIS with DOXIL/CAELYX Alone in Subjects with Advanced Relapsed Ovarian Cancer | |
| 100891 | Protocol | Adjuvant Androgen Deprivation Vs Mitoxantrone Plus Prednisone Plus Androgen Deprivation in Selected High Risk Prostate Cancer Patients Following Radical Prostatectomy, Phase III | |
| 100892 | Protocol | A Phase II Study of Neo-Adjuvant Cisplatin, Gemcitabine, and Bevacizumab, Followed by Radical Cystectomy for Patients with Muscle Invasive, Resectable, Non-Metastatic Transitional Cell Carcinoma (TCC) of the Bladder | |
| 100898 | Protocol | A Phase II Study of Submandibular Salivary Gland Transfer to the Submental Space Prior to Start of Radiation Treatment for Prevention of Radiation-Induced Xerostomia in Head and Neck Cancer Patients | |
| 100899 | Protocol | A Randomized Phase III Study of Conventional Whole Breast Irradiation (WBI) Vs Partial Breast Irradiation (PBI) for Women with Stage 0, I, or II Breast Cancer | |
| 100905 | Protocol | A Phase III Randomized Study of Cloretazine (VNP40101M) and Cytosine Arabinoside (AraC) in Patients with Acute Myeloid Leukemia in First Relapse | |
| 100906 | Protocol | Phase III Randomized Trial of Preoperative Chemotherapy Vs Preoperative Concurrent Chemotherapy and Thoracic Radiotherapy Followed by Surgical Resection and Consolidation Chemotherapy in Favorable Prognosis Patients with Stage IIIA (N2) Non-Small Cell Lung Cancer | |
| 100907 | Protocol | A Phase II, Open-Label Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Profile of ProxiniumTM in Patient with Advanced Squamous Cell Carcinoma of the Head and Neck who have Received at Least One Anti-Cancer Treatment Regimen for Advanced Disease | |
| 100908 | Protocol | A Randomized Open-Label Study of 400 mg Versus 800 mg of Gleevec/Glivec (imatinib mesylate) in Patients with Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CML-CP) Using Molecular Endpoints | |
| 100909 | Protocol | A Phase II Randomized Trial for Patients with Muscle-Invading Bladder Cancer Evaluating Transurethral Surgery and Bid Irradiation Plus Either Paclitaxel and Cisplatin or 5-Fluorouracil and Cisplatin Followed by Selective Bladder Preservation and Gemcitabine | |
| 100911 | Protocol | A Phase III Trial for Locally Recurrent, Previously Irradiated Head and Neck Cancer: Concurrent Re-Irradiation and Chemotherapy Vs Chemotherapy Alone | |
| 100915 | Protocol | A Phase III Randomized Open-Label Study Comparing Gemcitabine Plus Cetuximab (IMC-C225) Vs Gemcitabine as First-Line Therapy of Patients with Advanced Pancreas Cancer | |
| 100916 | Protocol | A Multicenter, Open-Label, Single-Arm Study of YONDELIS (trabectedin) for Subjects With Locally Advanced or Metastatic Soft Tissue Sarcoma Who Have Relapsed or Are Refractory to Standard of Care Treatment | |
| 100918 | Protocol | Phase II Study of Neoadjuvant Gemcitabine/Oxaliplatin and Cetuximab Followed by Surgery or Concurrent External Beam Radiation With Capecitabine for Patients With Locally Advanced Unresectable Nonmetastatic Pancreatic Cancer | |
| 100921 | Protocol | An Open-Label Study of Capecitabine and Docetaxel as Neoadjuvant Treatment for Patients with Recently Diagnosed HER2-neu Negative Breast Cancer Plus Trastuzamab for HER2-neu Positive Breast Cancer (Xena Trial) | |
| 100923 | Protocol | XELOX - A - DVS (Dense Vs Standard): A Randomized Study of Intermittent Capecitabine in Combination with Oxaliplatin (XELOX Q3W) and Bevacizumab versus Intermittent Capecitabine in Combination with Oxaliplatin (XELOX Q2W) and Bevacizumab as First-Line Therapy | |
| 100936 | Protocol | A Phase I/II Clinical Study to Determine the Maximum Tolerated Dose (MTD), Preliminary Safety, Efficacy, and PK Profile of HMPL-002 When Concurrently Administered With Standard Radiotherapy in Patients With Inoperable Locally Advanced Head and Neck Cancer | |
| 100943 | Protocol | A Multicenter Phase II Study of Sorafenib (BAY 43-9006) in Non-Gist Sarcomas | |
| 100944 | Protocol | A Phase III Trial of Carboplatin and Paclitaxel Plus Placebo Versus Carboplatin and Paclitaxel Plus Concurrent Bevacizumab Followed by Placebo, Versus Carboplatin and Paclitaxel Plus Concurrent and Extended Bevacizumab, In Women With Newly Diagnosed, Previously Untreated, Stage II (Suboptimal) and All Stage IV, Epithelial Ovarian or Primary Peritoneal Cancer | |
| 100945 | Protocol | Phase 2 Open-Label Study of Amonafide L-Malate in Combination with Cytarabine in Subjects with Secondary Acute Myeloid Leukemia (AML) | |
| 100946 | Protocol | An Open-Label, Single-Arm, Multi-Center, Phase 2 Study of Troxatyl (troxacitabine) Administered by Continuous Infusion in Patients with Acute Myeloid Leukemia (AML) in Second Salvage | |
| 100948 | Protocol | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm Study of the Effect of Intravenous AVE0005 (VEGF Trap) Administered Every 2 Weeks in Advanced Ovarian Cancer Patients with Recurrent Symptomatic Malignant Ascites | |
| 100949 | Protocol | Multicenter Randomized Phase II Study of Erlotinib, Cisplatin and Radiotherapy Vs Cisplatin and Radiotherapy in Patients with Stage III and IV Squamous Cell Carcinoma of the Head and Neck | |
| 100954 | Protocol | Phase II Evaluation of BAY 43-9006 (NSC-724772) in Patients with Recurrent or Metastatic Head and Neck Cancer | |
| 100955 | Protocol | Phase III Randomized, Placebo Controlled, Trial of Docetaxel Versus Docetaxel Plus ZD1839 (Iressa, Gefitinib) in Performance Status 2 or Previously Treated Patients with Recurrent or Metastatic Head and Neck Cancer | |
| 100958 | Protocol | A Phase III Randomized, Controlled Trial of Myocet, Trastuzumab and Paclitaxel versus Trastuzumab and Paclitaxel for First Line Therapy of Metastatic Breast Cancer | |
| 100959 | Protocol | Positron Emission Tomography Pre- and Post-treatment Assessment for Locally Advanced Non-small Cell Lung Carcinoma | |
| 100962 | Protocol | A Phase II Study of Active Immunotherapy With PANVAC or Autologous, Cultured Dendritic Cells Infected with PANVAC After Complete Resection of Hepatic Metastases of Colorectal Carcinoma | |
| 100964 | Protocol | A Phase II Study of Trastuzumab (NSC-688097) in Advanced High Grade Salivary Gland Carcinoma | |
| 100966 | Protocol | A Phase 3, Randomized, Open-Label Study Evaluating DN-101 in Combination with Docetaxel in Androgen-Independent Prostate Cancer (AIPC) (ASCENT-2) | |
| 100967 | Protocol | A Phase II Trial of Neoadjuvant Chemoradiation and Local Excision for uT2uN0 Rectal Cancer | |
| 100973 | Protocol | Phase I Study to Evaluate the Safety/Tolerability and Immunogenicity of V-930 in Patients with Cancers Expressing HER-2 and/or CEA | |
| 100975 | Protocol | A Randomized Multicenter Phase III Study of Taxane/Carboplatin/Cetuximab or Taxane/Carboplatin as First-Line Treatment for Patients with Advanced/Metastatic Non-Small Cell Lung Cancer | |
| 100979 | Protocol | Phase III Trial Comparing Conventional Adjuvant Temozolomide With Dose-Intensive Temozolomide in Patients with Newly Diagnosed Glioblastoma | |
| 100980 | Protocol | A Multicenter, Randomized, Double-Blind, Parallel-Arm, Two-Stage Study of the Efficacy and Safety of AVE0005 (VEGF Trap) Administered Intravenously Every 2 Weeks in Patients with Platinum-Resistant and Topotecan- and/or Liposomal Doxorubicin-Resistant Advanced Ovarian Cancer | |
| 100983 | Protocol | A Randomized Phase III Study of Sublobal Resection versus Sublobar Resection Plus Brachytherapy in High Risk Patients with Non-Small Cell Lung Cancer, 3 cm or Smaller | |
| 100984 | Protocol | An Open-label, Multicenter, Expanded Access Study of Oral AMN 107 in Adult Patients with Imatinib (Glivec/Gleevec) -Resistant or -Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase of Chronic Phase | |
| 100986 | Protocol | A Randomized, Double-Blind, Multicenter Study of Denosumab Compared with Zoledronic Acid (Zometa) in the Treatment of Bone Metastases in Subjects with Advanced Breast Cancer | |
| 100988 | Protocol | Phase II Study of Biweekly Gemcitabine and Paclitaxel (Gemtax) Combination in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN) | |
| 100991 | Protocol | Phase III Randomized Trial of Anastrozole Vs Anastrozole and Fulvestrant as First Line Therapy for Post Menopausal Women with Metastatic Breast Cancer | |
| 100992 | Protocol | A Randomized Phase 2 Study of the Anti-Angiogenesis Agent AG013736 in Combinations with Chemotherapy and Bevacizumab in Patients with Metastatic Colorectal Cancer Preceded by a Phase 1 Portion | |
| 100993 | Protocol | A Phase II Double Blind Placebo Controlled Trial to Assess Safety and Efficacy of Velafermin for Prevention of Oral Mucositis in Hematologic Cancer Patients Receiving Autologous Stem Cell Transplant | |
| 100994 | Protocol | A Randomized, Placebo-Controlled Phase III Trial of Yeast Derived GM-CSF Versus Peptide Vaccination Versus GM-CSF Plus Peptide Vaccination Versus Placebo in Patients with No Evidence of Disease After Complete Surgical Resection of Locally Advanced and/or Stage IV Melanoma | |
| 100997 | Protocol | A Randomised, Double-Blind, Multicenter Study of Denosumab Compared with Zoledronic Acid (Zometa) in the Treatment of Bone Metastases in Men with Hormone-Refractory Prostate Cancer | |
| 100998 | Protocol | A Phase II Study of Cloretazine for Elderly Patients with de novo Poor Risk Acute Myelogenous Leukemia | |
| 101000 | Protocol | Vitamin D Differentiation-Inducing Therapy to Enhance Intratumoral Anti-Tumor Immune Reactivity | |
| 101003 | Protocol | A Phase II Trial of Sequential Chemotherapy, Imatinib Mesylate (Gleevec, ST1571) (NSC# 716051, IND # 61135), and Transplantation for Adults With Newly Diagnosed PH+ Acute Lymphoblastic Leukemia by the CALGB and SWOG | |
| 101004 | Protocol | A Phase II Study of Double Induction Chemotherapy for Newly Diagnosed Non-L3 Adult Acute Lymphoblastic Leukemia with Investigation of Minimal Residual Disease and Risk of Relapse Following Maintenance Chemotherapy | |
| 101005 | Protocol | Randomized, Blinded, Multicenter Study of Proteinase 3 PR1 Peptide Mixed with Montanide ISA-51 VG Adjuvant and Administered with GM-CSF in Elderly Patients with AML in First Complete Remission or Adults in Second Complete Remission: A Pivotal Study | |
| 101008 | Protocol | A Phase I Dose-Escalation Study of R115777 (Tipifarnib) Plus PS-341 (Bortezomib) in Relapsed or Refractory Acute Leukemias | Moffit Cancer Center |
| 101012 | Protocol | A Phase III Trial Evaluating the Role of Exemestane Plus GnRH Analogue as Adjuvant Therapy for Premenopausal Women with Endocrine Responsive Breast Cancer | |
| 101013 | Protocol | A Randomized Trial of Adjuvant Chemotherapy with Standard Regimens, Cyclophosphamide, Methotraxane and Fluorouracil - (CMF) or Doxorubicin and Cyclophosphamide - (AC), Versus Capecitabine in Women 65 Years and Older with Node Positive or Node-Negative Breast Cancer | |
| 101014 | Protocol | A Randomized Phase III Trial of Exemestane Versus Anastrozole in Postmenopausal Women with Receptor Positive Primary Breast Cancer | |
| 101015 | Protocol | Neoadjuvant Chemoradiation Therapy with Oxaliplatin and Capecitabine for Patients with Surgically Resectable Gastric Cancer: A Pilot Phase II Trial with Molecular Correlates | |
| 101016 | Protocol | A Phase II/III Randomized Trial of Two Doses (Phase III-Standard vs. High) and Two High Dose Schedules (Phase II-Once vs Twice Daily) for Delivering Prophylactic Cranil Irradiation for Patients with Limited Disease Small Cell Lung Cancer | |
| 101021 | Protocol | A Randomized, Double-Blind, Multicenter Study of Denosumab Compared with Zoledronic Acid (Zometa) in the Treatment of Bone Metastases in Subjects with Advanced Cancer (Excluding Breast and Prostate Cancers) or Multiple Myeloma
| Amgen |
| 101022 | Protocol | A Phase 2, Open-label Trial of the Safety and Biological Effect of Pre-operative Peri-lymphatic Ultralow Dose IRX-2 (with Cyclophosphamide, Indomethacin, and Zinc) in Patients with Resectable Cancer of the Head and Neck
| |
| 101026 | Protocol | A Randomized, Double-Blind Phase III Trial of Adjuvant Sunitinib Vs Sorafenib Vs Placebo in Patients with Resected Renal Cell Carcinoma | |
| 101028 | Protocol | A Phase 2 Multicenter, Open-Label Study of CNTO 328 (Anti-IL-6 Monoclonal Antibody) in Combination with Mitoxantrone versus Mitoxantrone in Subjects with Metastatic Hormone-Refractory Prostate Cancer (HRPC) | |
| 101031 | Protocol | Cetuximab Plus Cisplatin, Irinotecan and Thoracic Radiotherapy (TRT) for Locally Advanced (non-metastatic), Clinically Unresectable Esophageal Cancer: A Phase II Trial with Molecular Correlates | |
| 101033 | Protocol | A Phase III Randomized Trial of Weekly Cisplatin and Radiation versus Cisplatin and Tirapazamine and Radiation in Stage IB2, IIA, IIB, IIIB and IVA Cervical Carcinoma Limited to the Pelvis | |
| 101036 | Protocol | A Phase II Pilot Investigation of the Relationship of Short Term Depo-Provera (Medroxyprogesterone Acetate)(NSC #27408) Exposure to the Morphologic, Biochemical, and Molecular Changes in Primary Endometroid Adenocarcinoma of the Uterine Corpus | |
| 101037 | Protocol | A Randomized, Open-Label, Controlled Phase II Trial of Docetaxel and Carboplatin Combination Chemotherapy With and Without Panitumumab in the First-line Treatment of Subjects with Metastatic or Recurrent Head and Neck Cancer | Amgen, Inc. |
| 101039 | Protocol | Peripheral Blood Molecular Staging of Breast Cancer: A Prospective Cohort Study Designed to Determine the Clinical Significance of Molecular Detection of Breast Cancer in the Peripheral Blood of Stage IV Breast Cancer Patients | |
| 101043 | Protocol | An International, Phase II, Randomized, Double-Blinded, Placebo-Controlled, Multi-Center Study to Assess the Efficacy of ZD6474 (ZACTIMA) versus Placebo in Subjects with Unresectable Locally Advanced or Metastatic Medullary Thyroid Cancer | |
| 101046 | Protocol | A Phase II Study of Pemetrexed Disodium (ALTIMA) Plus Bevacizumab in Patients with Stage IIIB Effusion or Stage IV Non-Small Cell Lung Cancer (Second-Line Treatment) | |
| 101047 | Protocol | The Influence of Five Years of Adjuvant Anastrozole or Exemestane on Bone Mineral Density in Postmenopausal Women with Primary Breast Cancer | |
| 101048 | Protocol | The Association of Breast Density Changes, Plasma Hormone Changes, and Breast Cancer Recurrence: A Companion Study to NCIC CTG MA.27 | |
| 101049 | Protocol | A Phase I Open-Label, Single-Arm, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Antitumor Activity of Continuous Intravenous Infusion of the Bispecific T-Cell Engager MEDI-538 in Adults with B-Cell Non-Hodgkin's Lymphoma Not Eligible for Curative Therapy | |
| 101050 | Protocol | EXamination of PNH, by Level Of CD59 on REd and white blood cells, in bone marrow syndromes (EXPLORE) | |
| 101054 | Protocol | A Phase II Study of Combination Rituxuman-CHOP and Bortezomib (Velcade) (R-CHOP-V) Induction Therapy Followed by Bortezomib Maintenance (VM) Therapy for Patients with Newly Diagnosed Mantle Cell Lymphoma | |
| 101055 | Protocol | A Phase II Trial of Combination Carboplatin, Paclitaxel, Cetuximab and Bevacizumab (NSC-704865) Followed by Cetuximab and Bevacizumab in Patients with Advanced Non-Small Cell Lung Cancer | |
| 101056 | Protocol | Randomized Phase II Trials of Neoadjuvant Combined Modality Therapy for Locally Advanced Rectal Cancer | |
| 101057 | Protocol | A Phase III Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Prochymal (Ex-vivo Cultured Adult Human Nesenchymal Stem Cells) Infusion for the Treatment of Steroid-Refractory Acute GVHD | |
| 101058 | Protocol | Phase I/II Study of Pre-Irradiation Chemotherapy with Methotrexate, Rituximab, and Temozolomide and Post-Irradiation Temozolomide for Primary Central Nervous System Lymphoma. | |
| 101059 | Protocol | Phase III Randomized Study of R-CHOP v. Dose-Adjusted EPOCH-R with Molecular Profiling in Untreated De Novo Diffuse Large B-Cell Lymphomas | |
| 101071 | Protocol | A randomized, double-blind, placebo-controlled, multicenter phase III study in patients with advanced carcinoid tumor receiving Sandostatin LAR and RAD001 10 mg/d or Sandostatin LAR and placebo. | |
| 101072 | Protocol | Phase II Study of Neoadjuvant Chemotherapy with NOV-002 and AC Followed by Docetaxel in Patients with Stage IIB-IIIC Breast Cancer | |
| 101081 | Protocol | A Randomized, Controlled, Open-label Study Evaluating the Efficacy and Tolerability of AMG 531 versus Medical Standard of Care as Chronic Therapy for Non-splenectomized Subjects with Immune (Idiopathic) Thrombocytopenic Purpura | |
| 101082 | Protocol | A Double-blind, Randomized, Placebo-Controlled Phase III Trial of Carboplatin, Paclitaxel and BAY 43-9006 versus Carboplatin, Paclitaxel and Placebo in Patients with Unresectable Locally Advanced or Stage IV Melanoma | |
| 101084 | Protocol | A Phase I Study to Evaluate the Safety/Tolerability and Immunogenicity of V930/V932 in Patients With Cancers Expressing HER-2 and/or CEA. | |
| 101089 | Protocol | A Phase III Trial Comparing Whole Brain Radiation and Stereotactic Radiosurgery Alone Versus with Temozolomide or Erlotinib in Patients with Non-Small Cell Lung Cancer and 1-3 Brain Metastases | |
| 101090 | Protocol | Phase II Trial of Dasatinib in Patients with Recurrent Glioblastoma Multiforme | |
| 101092 | Protocol | A Phase III, Randomized, Double-Blind, Controlled Study Comparing Clofarabine and Cytarabine versus Cytarabine Alone in Adult Patients >/= 60 Years Old with Acute Myelogenous Leukemia (AML) who have Relapsed or are Refractory after Receiving up to Two Prior Induction Regimens. | |
| 101102 | Protocol | A Phase 1/2, Open-Label, Dose Escalation Study to Assess the Safety and Pharmacokinetics of Recombinant Interleukin 21 (rIL-21) Administered Concomitantly with Sorafenib (Nexavar) in Subjects with Metastatic Renal Cell Carcinoma | ZymoGenetics |
| 101108 | Protocol | A Phase I/Ii Trial Of A Combination Of Paclitaxel And Trastuzumab With Daily Irradiation Or Paclitaxel Alone With Daily Irradiation Following Transurethral Surgery For Non -Cystectomy Candidates With Muscle-Invasive Bladder Cancer | |
| 101109 | Protocol | Azacitidine with rituximab, vincristine, and cyclophosphamide in refractory follicular lymphoma: a phase I trial | Pharmion |
| 101114 | Protocol | A Multicenter, Phase II, Randomized, Blinded, Placebo-Controlled Trial Evaluating the Efficacy and Safety of Sutent® With or Without Bevacizumab in First-Line Patients With Metastatic Renal Cell Cancer | |
| 101115 | Protocol | A Phase II Trial Of Neoadjuvant Therapy With Concurrent Chemotherapy And High Dose Radiotherapy Followed By Surgical Resection And Consolidative Therapy For
Locally Advanced Non-Small Cell Lung Carcinoma
| |
| 101116 | Protocol | A Multicenter, Randomized Double-Blind Phase II/III Study in the First-Line Treatment of Advanced Transitional Cell Carcinoma (TCC) of the Urothelium Comparing Vinflunine/Gemcitabine to Placebo/Gemcitabine in Patients who are Ineligible to Receive Cisplatin-Based Therapy (VINCENT) | |
| 101117 | Protocol | A Randomized, Double Blinded, Multi-Center Study to Estimate the Efficacy and Evaluate the Safety and Tolerability of Sorafenib in Combination with AMG 386 or Placebo as First Line Therapy for Subjects with Metastatic Clear Cell Carcinoma of the Kidney | |
| 101123 | Protocol | Phase III RituxanBEAM vs. BexxarBEAM with Autologous
Hematopoietic Stem Cell Tran splantation (ASCT) for Persistent or Relapsed Chemotherapy Sensitive Diffuse Large B-cell Non-Hodgkins Lymphoma | |
| 101128 | Protocol | An Open Label Randomized Controlled Dose Escalating Phase II Study of AS1411 Combined With Cytarabine In The Treatment of Patients With Primary Refractory Or Relapsed Acute Myeloid Leukemia | Antisoma Research Limited |
| 101134 | Protocol | A Randomized Phase IIb Placebo-controlled Study of R-ICE Chemotherapy (Rituximab, Ifosfamide, Carboplatin, and Etoposide) with and without SGN-40 (anti-CD40 humanized monoclonal antibody) for Second-line Treatment of Patients with Diffuse Large B-Cell Lymphoma (DLBCL) | Seattle Genetics |
| 101135 | Protocol | A Phase III Randomized Trial of Adjuvant Chemotherapy
With or Without Bevacizumab for Patients With
Completely Resected Stage IB (> 4 cm) - IIIA Non-Small
Cell Lung Cancer (NSCLC ) | |
| 101136 | Protocol | A Randomized, Multicenter, Phase III Study Comparing the
Combination of Pazopanib and Lapatinib versus Lapatinib
Monotherapy in Patients with ErbB2 over-expressing Inflammatory Breast Cancer | |
| 101144 | Protocol | A Phase II Trial of Radiation Therapy and Weekly Cisplatin Chemotherapy for the Treatment of Locally-Advanced Squamous Cell Carcinoma of the Vulva. | |
| 101145 | Protocol | A Randomized, Controlled Phase II Evaluation of Megestrol (Megace)in Differe Dose and Sequence in the Treatment of Endometrial Intraepithelial Neoplasia (EIN) from a Referred Cohort of Atypical Endometrial Hyperplasia | |
| 101148 | Protocol | A Phase II Study Of Concurrent Chemoradiotherapy Using Three-Dimensional Conformal Radiotherapy (3d-Crt) Or Intensity-Modulated Radiation Therapy (Imrt) + Bevacizumab (Bv) For Locally Or Regionally Advanced Nasopharyngeal Cancer | |
| 101149 | Protocol | A Phase II Trial of the Combination of OSI-774(Erlotinib; NSC-718781) and Bevacizumab (Rhumab VEGF; NSC-704865) In Stage IIIB and IV Bronchioloalveloar Carcinoma (BAC) and Adenocarcinoma with BAC features (AdenoBAC) | |
| 101150 | Protocol | Phase II Trial of the Combination of OSI-774 (Erlotinib; NSC-718781) and Bevacizumab (Rhumab VEGF; NSC-704865) In Never Smokers With Stage IIIB and IV Primary Lung Adenocarcinomas | |
| 101167 | Protocol | Phase III Trial Of Irinotecan -Based Chemotherapy Plus Cetuximab (Nsc-714692) With Or Without Bevacizumab (Nsc-704865) As Second-Line Therapy For Patients With Metastatic Colorectal Cancer Who Have Progressed On Bevacizumab With Either Folfox, Optimox Or Xelox | |
| 101170 | Protocol | Randomized Phase 3 Trial To Evaluate Radiopharmaceuticals And Zoledronic Acid In The Palliation Of Osteoblastic Metastases From Lung, Breast, And Prostate Cancer | |
| 101171 | Protocol | Program for the Assessment of Clinical Cancer Tests (PACCT-1): Trial Assigning IndividuaLized Options for Treatment:
The TAILORx Trial | |
| 101177 | Protocol | A Phase II Trial of Cytarabine and Clofarabine in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL). | |